Walgreens Says Insulin Pen Settlement Suit Has No 'Heat'
An attorney for pharmacy giant Walgreens' parent company told a Delaware vice chancellor on Monday that a stockholder derivative complaint seeking more than $200 million from directors who allegedly ignored intentional...To view the full article, register now.
Already a subscriber? Click here to view full article